Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin with or without Risperidone in Treatment-resistant Depression (SYNVEST)
NCT06512220Phase 2Recruiting
- Sponsor
- Center for Addiction and Mental Health
- Start
- Apr 2025
- Primary completion
- Apr 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2 trial of psilocybin in treatment-resistant depression (TRD) (2 arms), sponsored by Center for Addiction and Mental Health. Primary endpoint: Feasibility of obtaining PET imaging scans at Day 28. Started Apr 2025; status: recruiting.
02
Drugs
psilocybin
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT06512220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06512220.